ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 2 مورد

Histological diagnosis and the common molecular events of WHO-recognized PLGG

Histological diagnosis and the common molecular events of WHO-recognized PLGG
Histological diagnosis Common molecular events
Glial tumors
Pilocytic astrocytoma
  • KIAA1549-BRAF (70 to 80%)
  • FGFR1-TACC1 (3 to 5%)
  • FGFR1 SNV (3 to 5%)
  • BRAF p.V600E (3 to 5%)
  • Other BRAF fusions (2 to 5%)
  • CRAF fusions (2 to 5%)
  • PTPN11 SNV (2 to 5%)
  • KRAS/HRAS SNV (2 to 5%)
Subependymal giant cell astrocytoma
  • TSC1/2 SNV (85 to 95%)
Diffuse astrocytoma
  • BRAF p.V600E (20 to 40%)
  • MYBL1 alteration (5 to 10%)
  • KIAA1549-BRAF (5 to 10%)
  • FGFR1 SNV (2 to 5%)
  • H3.3 p.K27M (2 to 5%)
  • IDH1 p.R132H (2 to 5%)
  • Other RTK SNV/fusions (2 to 3%)
Pleomorphic xanthoastrocytoma
  • BRAF p.V600E (80 to 90%)
Oligodendroglioma
  • FGFR1-TKD duplication (10 to 20%)
  • FGFR1 SNV (10 to 20%)
  • BRAF p.V600E (5 to 10%)
  • FGFR1-TACC1 (3 to 5%)
  • IDH1 p.R132H (3 to 5%)
  • 1p/19q co-deletion (3 to 5%)
Mixed glioneuronal tumors
Ganglioglioma
  • BRAF p.V600E (40 to 50%)
  • KIAA1549-BRAF (10 to 15%)
Desmoplastic infantile astrocytoma and ganglioglioma
  • BRAF pV600E/D (40 to 60%)
  • FGFR1 SNV (5 to 10%)
  • KIAA1549-BRAF (2 to 5%)
Dysembryoplastic neuroepithelial tumor
  • FGFR1-TKD duplication (20 to 30%)
  • FGFR1 SNV (20 to 30%)
  • FGFR1-TACC1 (10 to 15%)
  • Other RTK SNV/fusions (5 to 10%)
  • BRAF p.V600E (5 to 10%)
Papillary glioneuronal tumor
  • SLC44A1-PRKCA (80 to 90%)
Rosette-forming glioneuronal tumor
  • PIK3CA SNV (20 to 30%)
  • KIAA1549-BRAF (20 to 30%)
  • FGFR1 SNV (20 to 30%)
Angiocentric glioma
  • MYB (80 to 90%)
Chordoid glioma of third ventricle
  • PRKCA SNV (80 to 90%)
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY)
  • BRAF p.V600E (30 to 40%)
  • FGFR2/3 fusions (30 to 40%)
Multinodular and vacuolating neuronal tumor (MVNT)
  • MAP2K1 SNV/Indel (50 to 60%)
  • BRAF p.V600E (5 to 10%)
  • Other BRAF SNV (5 to 10%)
  • FGFR2 fusions (3 to 5%)
IDH: isocitrate dehydrogenase; Indel: insertion-deletion; PLGG: pediatric low-grade glioma; RTK: receptor tyrosine kinase; SNV: single nucleotide variant; TKD: tyrosine kinase domain; WHO: World Health Organization.
From: Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 2020; 8:30. Copyright © 2020 The Authors. https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-020-00902-z (Accessed on September 27, 2024). Reproduced under the terms of the Creative Commons Attribution License 4.0.
Graphic 146234 Version 1.0